Time：2025-12-12
Recently, the ZhejiangProvincial Department of Economy and Information Technology announced theproposed list of 2025 Zhejiang Provincial Enterprise Technology Centers.Chinese Peptide Company, a subsidiary of Medtide Pharmaceuticals, successfullymade the list by virtue of its profound technical innovation accumulation andoutstanding industrial leading capacity. This marks the dual authoritativerecognition of Chinese Peptide Company's technological innovation strength andR&D system construction by both provincial and municipal competentauthorities.
The recognition of enterprise technology centers thistime was strictly carried out in accordance with the requirements of the Noticeon Printing and Distributing the Measures for the Administration of HangzhouMunicipal Enterprise Technology Centers (Hang Jingxinlian Zhineng〔2018〕No. 81) and the Notice on Carrying out theRecognition and Re-evaluation Work of 2025 Hangzhou Municipal EnterpriseTechnology Centers (Hang Jingxin Jichuang〔2025〕No. 56). After multiple rigorous procedures including independent applicationby enterprises, recommendation by district and county economic and informationdepartments, review by municipal-level departments, and expert evaluation, atotal of 170 enterprises were finally selected as municipal enterprisetechnology centers from a large number of applicants. Chinese Peptide Companystood out smoothly with its technological advantages in the fields of peptidesand oligonucleotides. As an important part of Hangzhou's industrial innovationsystem, the recognition of enterprise technology centers aims to commendbackbone enterprises in the industry with strong innovation capabilities andsound innovation mechanisms. The selection of Chinese Peptide Company is a highaffirmation of its comprehensive strength in technological R&D, achievementtransformation, talent training and other aspects.
Winning the recognition as both provincial and municipalenterprise technology center is not only an honor but also a responsibility forChinese Peptide Company. In the future, taking the enterprise technology centeras a new development platform, Chinese Peptide Company will continue toincrease R&D investment, deepen industry-university-research collaborativeinnovation, break through more key core technologies in the fields of peptides andoligonucleotides, contribute to building Hangzhou into a global innovation hub,and boost the high-quality development of the global biopharmaceuticalindustry.
About Chinese Peptide Company (One Sentence)
Chinese Peptide Company is a peptide and oligonucleotide-focusedContract Research, Development, and Manufacturing Organization (CRDMO),offering full-cycle services ranging from early-stage discovery, pre-clinicalresearch and clinical development to commercial-stage production.
